South African variant can 'break through' Pfizer vaccine, new study in Israel finds

  • Scientists studied 400 people who tested positive at least 14 days after shot
  • Variant was eight times more prevalent in those who had two shots than none 
  • It was seen in 5.4% of people with 2 doses - but 0.7% of people without any  

By Jemma Carr For Mailonline and Rory Tingle For Dailymail.com and Reuters

Published: | Updated:

The mutant South African Covid-19 variant can 'break through' the Pfizer jab, a study has found.

Scientists studied 400 people who had tested positive for coronavirus at least 14 days after receiving one or two doses of the jab - and 400 who tested positive with no vaccine.

The variant was eight times more prevalent in those who had two jabs than none. It was seen in 5.4 per cent of people with two doses - but 0.7 per cent of people without any.

The South African strain — called B.1.351 — has key mutations on its spike protein which make scientists fear might make it hard for the immune system to recognise

The South African strain — called B.1.351 — has key mutations on its spike protein which make scientists fear might make it hard for the immune system to recognise

This suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain that has come to comprise nearly all COVID-19 cases in Israel, the researchers said.

'We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. 

This means that the South African variant is able, to some extent, to break through the vaccine's protection,' said Tel Aviv University's Adi Stern.

The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.

They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.

Pfizer and BioNTech could not be immediately reached for comment outside business hours.

The companies said on April 1 that their vaccine was around 91% effective at preventing COVID-19, citing updated trial data that included participants inoculated for up to six months.

A man receives a shot of the coronavirus vaccine on April 10 in Immokalee, Florida

A man receives a shot of the coronavirus vaccine on April 10 in Immokalee, Florida 

In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of COVID-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.

Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a robust defence.

While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Stern.

'Even if the South African variant does break through the vaccine's protection, it has not spread widely through the population,' said Stern, adding that the British variant may be 'blocking' the spread of the South African strain.

Almost 53% of Israel's 9.3 million population has received both Pfizer doses.

Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding, with infection rates, severe illness and hospitalizations dropping sharply. About a third of Israelis are below the age of 16, which means they are still not eligible for the shot.

A nurse prepares the Pfizer Covid-19 vaccine at a pop-up center in Los Angeles

A nurse prepares the Pfizer Covid-19 vaccine at a pop-up center in Los Angeles 

Covid-19Pfizer

Most watched News videos